InvestSMART

Resonance Health Limited (ASX:RHT)

ALERT: Price-sensitive ASX Announcement for RHT
Current share price for RHT : $0.060 0.013 (27.66%)+
Announcement
Release
24 Jul 2026 9:54AM
Price at Release
$0.047
Full Release
download
Summary
Resonance Health Limited reported strong financial performance for Q4 and full-year FY26, with consistent positive cash flow and a robust cash position. The company achieved significant milestones, including completing patient recruitment for a major clinical trial and expanding its SaMD services and clinic network. Resonance Health is well-positioned for strategic growth in FY27, supported by a strong contract pipeline and a strengthened financial and governance structure.
Key Points
  • Resonance Health Limited reported Q4 FY26 cash receipts of $4.0M and a net positive operating cash inflow of $0.7M.
  • For FY26, the company had cash receipts of $14.3M with a net positive operating cash inflow of $2.9M.
  • The company maintained positive operating cash flow throughout all four quarters of FY26.
  • Cash at the bank was $4.8M at the end of the quarter, with a net cash position of $2.3M after accounting for bank debt.
  • The company's major $13.8M pharma clinical trial achieved its 60-patient recruitment target.
  • Resonance Health is expanding its Software-as-a-Medical Device (SaMD) services and TrialsWest clinic network.
  • The company completed recruitment for a new Non-Invasive MRI Liver Fibrosis trial.
  • Resonance Health is positioned to pursue strategic growth initiatives in FY27 with a strengthened board and cash position.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.